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definitively established due to some controversial findings, 
the possible reasons of which demand further research with 
prospective and uniform protocols and analysis, great number 
of pts and adequate follow-up period. 
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Purpose or Objective: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. 
 
Material and Methods: To synthesize and compare available 
evidence considering the effectiveness of carbon-ion 
radiotherapy for stage I non-small cell lung cancer. Methods: 
A comprehensive search was conducted in the Cochrane 
Library, PubMed, EMBASE,Web of Science and Chinese 
Biomedical Literature Database (from inception to Feb 2015). 
Selection of studies, and extracting data were performed by 
two reviewers independently. Outcomes were analyzed by 
random-effects model meta-analysis and reported as odds 
ratio (OR) with 95% confidence intervals (CI). The meta-
analysis was conducted with STATA 12.0 software. 
 
Results: Eight trials(369 patients) were included, the meta 
analysis showed that the one year local control rate(LCR) was 
OR=0.89(95%CI:0.81,0.90),two years LCR was 
OR=0.81(95%CI:0.72,0.89),three years LCR was 
OR=0.64(95%CI:0.55,0.73),four years LCR was 
OR=0.23(95%CI:0.13,0.33) and five years LCR was 
OR=0.70(95%CI:0.67,0.73).the one year overall survival(OS) 
was OR=0.94(95%CI:0.88,0.99),two years OS was 
OR=0.85(95%CI:0.70,1.00),three years OS was 
OR=0.64(95%CI:0.50,0.78), four years OS was 
OR=0.29(95%CI:0.18,0.40) and five years OS was 
OR=0.34(95%CI:0.19,0.49).the one year progression-free 
survival(PFS) was OR=0.79(95%CI:0.69,0.89), two years PFS 
was OR=0.63(95%CI:0.52,0.75),three years PFS was 
OR=0.39(95%CI:0.28,0.51),four years PFS was 
OR=0.20(95%CI:0.10,0.29) and five years PFS was 
OR=0.08(95%CI:0.02,0.15).the recurrence was 
OR=0.46(95%CI:0.39,0.53) and distant metastasis was 
OR=0.20(95%CI:0.14,0.26). 
 
Conclusion: Carbon beam radiotherapy, which is an excellent 
new modality in terms of a high local control and survival, 
may be a valid alternative to surgery for Stage I cancer, 
especially for elderly and inoperable patients. 
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Purpose or Objective: Stereotactic ablative radiotherapy is 
an emerging non-invasive technique for the treatment of lung 
lesions. Both primary lesions and metastases may benefit 
from this approach, even in patients with low respiratory 
reserve. This work describes and evaluates institutional 
experience of SABR in lung location. 
 
Material and Methods: From May´12 to November´14, 82 
lesions in 67 patients were irradiated. 57 lesion were primary 
lung tumors and 25 metastases. Immobilization systems used 
in each patient was abdominal compressor and vacuum 
cushion o head-and-shoulders mask. An ITV was defined using 
three CT scans in three different phases of the respiratory 
cycle or with 4D RPM-Varian® system. The PTV was obtained 
by uniformly 5 mm ITV expanding. BED prescription was 
always over 100 Gy10 in 3-8 fractions following a risk-adapted 
protocol. 8 patient treatments were performed on a Clinac 
iXTM and 74 treatments on a TruebeamTM with high 
definition MLC. Volumetric modulated arc therapy 
(RapidArcTM) was mostly used, and image-guided RT was 
performed with cone-beam CT (CBCT). Intra-fraction 
movement was controlled by post-treatment CBCT and infra-
red ExacTrac. 
 
Results: Median age was 75y.o.(44-89). The median GTV/PTV 
size was 3.2/27.15cm3 (0.2-129.9/5.90-263.90). Intra-
fraction movement in all cases was less than 5mm according 
to post-treatment CBCT. At a median follow-up of 7(1-30) 
months, overall l local control was 92.7%, 89.5% for primary 
lesions and 100% for metastases. Mean overall survival was 18 
months for primary lesion (14.7-21.33 [95%]). No toxicities 
over G3 have been collected. 
 
Conclusion: VMAT based ablative radiotherapy achieves 
excellent control rates in both primary lesions and 
metastases. Overall survival also depends on specific 
characteristics of the patient. 
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Purpose or Objective: Receiving Radio(chemo)therapy 
[R(C)T] for pulmonary tumors some patients have or develop 
necrosis or fistulae (N/F) within the area of the treated 
tumor. Partially such N/F result in fatal complications like 
mediastinitis or pneumonia whereas other affected patients 
achieve good local control rates with long term survival after 
R(C)T. By retrospectively analyzing such cases we are aiming 
at identifying factors that might have an impact on the 
course of disease and should pre-therapeutically be 
considered in future. 
 
Material and Methods: Retrospective analysis of patients 
coming up with N/F in temporal association with chest RT 
applied at the University Medical Center Freiburg from 2006 
to 2013. Clinical and radiation parameters have been 
evaluated, acute and late toxicity, complications, clinical 
and imaging follow up have been assessed and will be 
analyzed with respect to local control and overall survival. 
 
Results: We identified 40 patients irradiated for pulmonary 
malignancies (mainly centrally located NSCLC, UICC IIIB/IV; 
16 female, 24 male; median age 64 years; 15 squamous cell-, 
15 adenocarcinoma, 10 other) who developed N/F in 
temporal association with chest RT. Intention of treatment 
was curative in 31 and palliative in 9 patients. 25 patients 
received R(C)T, 15 received RT alone with a median total 
dose of 54 Gy (14-72Gy). 26 patients revealed a necrotic 
primary tumor, 6 additionally necrotic lymph node 
metastases (LNM), 8 necrotic LNM, exclusively. In 34 lesions 
necrosis was found previous to RT, in 3 cases it occurred 
during, in 3 cases after RT.14 patients showed fistulae, all 
fistulae with esophageal or mediastinal involvement emerged 
after RT. For 16 patients G3, for 6 G4 toxicities have been 
reported, one patient died in consequence of an esophago-
tracheal fistula. All patients with N/F-connection to the 
esophagus revealed toxicities ≥G3, whereas some patients 
with centrally necrotic tumor and fistula without esophageal 
involvement revealed excellent long term follow ups. Median 
survival was 12,6 months (median FU 6,9 months). All 
patients with esophago-tracheal fistula died before reaching 
the median. Histology and location of the necrotic lesions 
didn’t show any significant impact on survival. 
 
Conclusion: R(C)T of pulmonary malignancies for patients 
with N/ F can be associated with high toxicity. One essential 
factor with impact on the clinical course seems to be the 
